BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 27591952)

  • 1. Development of recombinant vaccine candidate molecule against Shigella infection.
    Chitradevi STS; Kaur G; Sivaramakrishna U; Singh D; Bansal A
    Vaccine; 2016 Oct; 34(44):5376-5383. PubMed ID: 27591952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-administration of rIpaB domain of Shigella with rGroEL of S. Typhi enhances the immune responses and protective efficacy against Shigella infection.
    Chitradevi ST; Kaur G; Uppalapati S; Yadav A; Singh D; Bansal A
    Cell Mol Immunol; 2015 Nov; 12(6):757-67. PubMed ID: 25640657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of
    Turbyfill KR; Clarkson KA; Vortherms AR; Oaks EV; Kaminski RW
    mSphere; 2018; 3(2):. PubMed ID: 29600284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice.
    Heine SJ; Franco-Mahecha OL; Chen X; Choudhari S; Blackwelder WC; van Roosmalen ML; Leenhouts K; Picking WL; Pasetti MF
    Immunol Cell Biol; 2015 Aug; 93(7):641-52. PubMed ID: 25776843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous expression of Intimin and IpaB fusion protein in Lactococcus lactis and its mucosal delivery elicit protection against pathogenicity of Escherichia coli O157 and Shigella flexneri in a murine model.
    Sagi S; Konduru B; Parida M
    Int Immunopharmacol; 2020 Aug; 85():106617. PubMed ID: 32464569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes.
    Heine SJ; Diaz-McNair J; Andar AU; Drachenberg CB; van de Verg L; Walker R; Picking WL; Pasetti MF
    J Immunol; 2014 Feb; 192(4):1630-40. PubMed ID: 24453241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broadly protective Shigella vaccine based on type III secretion apparatus proteins.
    Martinez-Becerra FJ; Kissmann JM; Diaz-McNair J; Choudhari SP; Quick AM; Mellado-Sanchez G; Clements JD; Pasetti MF; Picking WL
    Infect Immun; 2012 Mar; 80(3):1222-31. PubMed ID: 22202122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cloning, expression and characterization of heat shock protein 60 (groEL) of Salmonella enterica serovar Typhi and its role in protective immunity against lethal Salmonella infection in mice.
    Paliwal PK; Bansal A; Sagi SS; Mustoori S; Govindaswamy I
    Clin Immunol; 2008 Jan; 126(1):89-96. PubMed ID: 18024219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine.
    Martinez-Becerra FJ; Chen X; Dickenson NE; Choudhari SP; Harrison K; Clements JD; Picking WD; Van De Verg LL; Walker RI; Picking WL
    Infect Immun; 2013 Dec; 81(12):4470-7. PubMed ID: 24060976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.
    Heine SJ; Diaz-McNair J; Martinez-Becerra FJ; Choudhari SP; Clements JD; Picking WL; Pasetti MF
    Vaccine; 2013 Jun; 31(28):2919-29. PubMed ID: 23644075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An approach to chimeric subunit immunogen provides efficient protection against toxicity, type III and type v secretion systems of Shigella.
    Felegary A; Nazarian S; Kordbacheh E; Fathi J; Minae ME
    Int Immunopharmacol; 2021 Nov; 100():108132. PubMed ID: 34508943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Functional B-Cell Epitopes at the Amino Terminus of
    Li S; Han X; Upadhyay I; Zhang W
    Appl Environ Microbiol; 2022 Aug; 88(15):e0038422. PubMed ID: 35856689
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of adjuvants on immune response and protective immunity elicited by recombinant Hsp60 (GroEL) of Salmonella typhi against S. typhi infection.
    Bansal A; Paliwal PK; Sagi SS; Sairam M
    Mol Cell Biochem; 2010 Apr; 337(1-2):213-21. PubMed ID: 19851830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model.
    Yagnik B; Sharma D; Padh H; Desai P
    Vaccine; 2019 May; 37(23):3097-3105. PubMed ID: 31047673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A broadly immunogenic polyvalent
    Li S; Anvari S; Ptacek G; Upadhyay I; Kaminski RW; Sack DA; Zhang W
    Infect Immun; 2023 Nov; 91(11):e0031623. PubMed ID: 37795982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of S. Typhi GroEL and IL-22 gene augments immune responses against Salmonella infection.
    Kaur G; STS C; Nimker C; Singh M; Saraswat D; Saxena S; Bansal A
    Immunol Cell Biol; 2013; 91(10):642-51. PubMed ID: 24145856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Live Attenuated Bivalent Oral Vaccine Against Shigella sonnei Shigellosis and Typhoid Fever.
    Wu Y; Chakravarty S; Li M; Wai TT; Hoffman SL; Sim BK
    J Infect Dis; 2017 Jan; 215(2):259-268. PubMed ID: 27803169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV; Turbyfill KR
    Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal immunization of recombinant HSP70 (DnaK) of Salmonella Typhi induces a predominant Th2 response and protective immunity in mice against lethal Salmonella infection.
    Paliwal PK; Bansal A; Sagi SS; Sairam M
    Vaccine; 2011 Sep; 29(38):6532-9. PubMed ID: 21767594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico design of a novel chimeric shigella IpaB fused to C terminal of clostridium perfringens enterotoxin as a vaccine candidate.
    Arabshahi S; Nayeri Fasaei B; Derakhshandeh A; Novinrooz A
    Bioengineered; 2018 Jan; 9(1):170-177. PubMed ID: 29091543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.